Table 3 Test performance inputs of cytology and Cobas® HPV test (pooled and 16/18 genotyping)
Input | Value | Source |
|---|---|---|
Cytology (threshold ASCUS) | ||
Sensitivity CIN2 | 52.6% | Castle et al. (2011) [28] |
Sensitivity CIN3 | 52.8% | Castle et al. (2011) [28] |
Sensitivity CxCa | 52.8% | assumed to be equivalent to CIN3 |
Specificity CIN2+ | 76.1% | Castle et al. (2011) [28] |
Cytology (threshold LSIL) | ||
Sensitivity CIN2 | 39.2% | Castle et al. (2011) [28] |
Sensitivity CIN3 | 40.1% | Castle et al. (2011) [28] |
Sensitivity CxCa | 40.1% | assumed to be equivalent to CIN3 |
Specificity CIN2 | 86.5% | Castle et al. (2011) [28] |
Cytology (threshold HSIL) | ||
Sensitivity CIN2 | 20.3% | Castle et al. (2011) [28] |
Sensitivity CIN3 | 26.2% | Castle et al. (2011) [28] |
Sensitivity CxCa | 26.2% | assumed to be equivalent to CIN3 |
Specificity CIN2 | 98.3% | Castle et al. (2011) [28] |
Cobas® HPV test (pooled) | ||
Sensitivity CIN2 | 88.2% | Castle et al. (2011) [28] |
Sensitivity CIN3 | 92.0% | Castle et al. (2011) [28] |
Sensitivity CxCa | 92.0% | assumed to be equivalent to CIN3 |
Specificity CIN2 | 57.8% | Castle et al. (2011) [28] |
Cobas® HPV test with genotyping 16/18 | ||
Sensitivity 16/18 CIN2 | 51.8% | Castle et al. (2011) [28] |
Sensitivity 16/18 CIN3 | 59.5% | Castle et al. (2011) [28] |
Sensitivity 16/18 CxCa | 65.3% | Castle et al. (2011) [28] |
Specificity CIN2 | 75.3% | Castle et al. (2011) [28] |